Literature DB >> 15479876

Targeting the Jak/STAT pathway for immunosuppression.

J J O'shea1.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15479876      PMCID： PMC1766780          DOI： 10.1136/ard.2004.028290

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  67 in total

Review 1.  Lineage commitment in lymphocytes: controlling the immune response.

Authors:  L H Glimcher
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain.

Authors:  P Mella; R F Schumacher; T Cranston; G de Saint Basile; G Savoldi; L D Notarangelo
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

Review 3.  Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.

Authors:  L D Notarangelo; P Mella; A Jones; G de Saint Basile; G Savoldi; T Cranston; M Vihinen; R F Schumacher
Journal:  Hum Mutat       Date:  2001-10       Impact factor: 4.878

Review 4.  The use of antibodies against the IL-2 receptor in transplantation.

Authors:  T A Waldmann; J O'Shea
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

5.  Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex.

Authors:  H Asao; C Okuyama; S Kumaki; N Ishii; S Tsuchiya; D Foster; K Sugamura
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

6.  Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology.

Authors:  Ulla-Angela Temann; Prabir Ray; Richard A Flavell
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 7.  Interleukin-7: master regulator of peripheral T-cell homeostasis?

Authors:  T J Fry; C L Mackall
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

8.  Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.

Authors:  A Puel; S F Ziegler; R H Buckley; W J Leonard
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

Review 9.  The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c.

Authors:  W J Leonard; M Noguchi; S M Russell; O W McBride
Journal:  Immunol Rev       Date:  1994-04       Impact factor: 12.988

Review 10.  Advances in the understanding and treatment of human severe combined immunodeficiency.

Authors:  R H Buckley
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505
View more
  37 in total

Review 1.  Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.

Authors:  Charles J Malemud; David E Blumenthal
Journal:  World J Orthop       Date:  2014-09-18

2.  Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis.

Authors:  J G Walker; M J Ahern; M Coleman; H Weedon; V Papangelis; D Beroukas; P J Roberts-Thomson; M D Smith
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

Review 3.  Janus kinase 3: the controller and the controlled.

Authors:  Wei Wu; Xiao-Hong Sun
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2011-11-29       Impact factor: 3.848

4.  A mechanism underlying NOTCH-induced and ubiquitin-mediated JAK3 degradation.

Authors:  Wei Wu; Xiao-Hong Sun
Journal:  J Biol Chem       Date:  2011-10-03       Impact factor: 5.157

5.  The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.

Authors:  Huizhi Wang; Jonathan Brown; Shegan Gao; Shuang Liang; Ravi Jotwani; Huaxin Zhou; Jill Suttles; David A Scott; Richard J Lamont
Journal:  J Immunol       Date:  2013-06-24       Impact factor: 5.422

6.  Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.

Authors:  J G Walker; M J Ahern; M Coleman; H Weedon; V Papangelis; D Beroukas; P J Roberts-Thomson; M D Smith
Journal:  Ann Rheum Dis       Date:  2006-06-07       Impact factor: 19.103

Review 7.  Cardiovascular effects of approved drugs for rheumatoid arthritis.

Authors:  Fabiola Atzeni; Javier Rodríguez-Carrio; Călin D Popa; Michael T Nurmohamed; Gabriella Szűcs; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2021-04-08       Impact factor: 20.543

Review 8.  Current and potential immune therapies and vaccines in the management of psoriasis.

Authors:  Benjamin H Kaffenberger; Grace L Lee; Kelly Tyler; Derek V Chan; Wael Jarjour; Maria E Ariza; Marshall V Williams; Henry K Wong
Journal:  Hum Vaccin Immunother       Date:  2014-02-03       Impact factor: 3.452

Review 9.  JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.

Authors:  Silvio Danese; Matthew Grisham; Jennifer Hodge; Jean-Baptiste Telliez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-25       Impact factor: 4.052

10.  Generation of a novel CD30+ B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis.

Authors:  K Higashioka; Y Kikushige; M Ayano; Y Kimoto; H Mitoma; M Kikukawa; M Akahoshi; Y Arinobu; T Horiuchi; K Akashi; H Niiro
Journal:  Clin Exp Immunol       Date:  2020-07-14       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.